Integrating Genomic Testing for Melanoma Into Your Practice
Main Article Content
Keywords
melanoma, skin cancer, genetic testing, 31-GEP, 2-GEP, prognosis, diagnosis, pigmented lesion
Abstract
Abstract not available.
References
1. Mossbacher U, Knollmayer S, Binder M, Steiner A, Wolff K, Pehamberger H. Increased nuclear volume in metastasizing “thick” melanomas. J Invest Dermatol. 1996;106(3):437-440. doi:10.1111/1523-1747.ep12343580
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-908.
3. Morton DL, Thompson JF, Cochran AJ, et al. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. N Engl J Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460
4. More people die from thin melanomas than thick melanomas. Accessed December 13, 2021. https://www.mdedge.com/internalmedicine/article/87682/melanoma/more-people-die-thin-melanomas-thick-melanomas
5. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):481-486. doi:10.1200/JCO.2009.24.7734
6. Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018;1(1):e180086. doi:10.1001/jamanetworkopen.2018.0086
7. Puglisi R, Bellenghi M, Pontecorvi G, Pallante G, Carè A, Mattia G. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers. 2021;13(12):2875. doi:10.3390/cancers13122875
8. Brouha B, Ferris L, Skelsey M, et al. Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings From a Large U.S. Registry Study. SKIN J Cutan Med. 2021;5(1):13-18. doi:10.25251/skin.5.1.3
9. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(1):175-183. doi:10.1158/1078-0432.CCR-13-3316
10. Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019;41(4):871-879. doi:10.1002/hed.25473
11. Mirsky R, Prado G, Svoboda R, Glazer A, Rigel D. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. J Drugs Dermatol JDD. 2018;17(11):1220-1223.
12. Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8(5):2205-2212. doi:10.1002/cam4.2128
13. Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. SKIN J Cutan Med. 2018;2(2):111-121. doi:10.25251/skin.2.2.3
14. Durham AB, Schwartz JL, Lowe L, et al. The natural history of thin melanoma and the utility of sentinel lymph node biopsy. J Surg Oncol. 2017;116(8):1185-1192. doi:10.1002/jso.24765
15. Schuitevoerder D, Heath M, Cook RW, et al. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. J Drugs Dermatol JDD. 2018;17(2):196-199.
16. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol OncolJ Hematol Oncol. 2017;10(1):152. doi:10.1186/s13045-017-0520-1
17. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912
18. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912
19. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76(1):114-120.e2. doi:10.1016/j.jaad.2016.07.038
20. Skelsey M, Brouha B, Rock J, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. SKIN J Cutan Med. 2021;5(5):512-523. doi:10.25251/skin.5.5.9
21. Ferris LK, Rigel DS, Siegel DM, et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatol Online J. 2019;25(5):13030/qt61w6h7mn.
22. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017;357:j2813. doi:10.1136/bmj.j2813
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-908.
3. Morton DL, Thompson JF, Cochran AJ, et al. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. N Engl J Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460
4. More people die from thin melanomas than thick melanomas. Accessed December 13, 2021. https://www.mdedge.com/internalmedicine/article/87682/melanoma/more-people-die-thin-melanomas-thick-melanomas
5. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):481-486. doi:10.1200/JCO.2009.24.7734
6. Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018;1(1):e180086. doi:10.1001/jamanetworkopen.2018.0086
7. Puglisi R, Bellenghi M, Pontecorvi G, Pallante G, Carè A, Mattia G. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers. 2021;13(12):2875. doi:10.3390/cancers13122875
8. Brouha B, Ferris L, Skelsey M, et al. Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings From a Large U.S. Registry Study. SKIN J Cutan Med. 2021;5(1):13-18. doi:10.25251/skin.5.1.3
9. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(1):175-183. doi:10.1158/1078-0432.CCR-13-3316
10. Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019;41(4):871-879. doi:10.1002/hed.25473
11. Mirsky R, Prado G, Svoboda R, Glazer A, Rigel D. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. J Drugs Dermatol JDD. 2018;17(11):1220-1223.
12. Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8(5):2205-2212. doi:10.1002/cam4.2128
13. Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. SKIN J Cutan Med. 2018;2(2):111-121. doi:10.25251/skin.2.2.3
14. Durham AB, Schwartz JL, Lowe L, et al. The natural history of thin melanoma and the utility of sentinel lymph node biopsy. J Surg Oncol. 2017;116(8):1185-1192. doi:10.1002/jso.24765
15. Schuitevoerder D, Heath M, Cook RW, et al. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. J Drugs Dermatol JDD. 2018;17(2):196-199.
16. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol OncolJ Hematol Oncol. 2017;10(1):152. doi:10.1186/s13045-017-0520-1
17. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912
18. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912
19. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76(1):114-120.e2. doi:10.1016/j.jaad.2016.07.038
20. Skelsey M, Brouha B, Rock J, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. SKIN J Cutan Med. 2021;5(5):512-523. doi:10.25251/skin.5.5.9
21. Ferris LK, Rigel DS, Siegel DM, et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatol Online J. 2019;25(5):13030/qt61w6h7mn.
22. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017;357:j2813. doi:10.1136/bmj.j2813
Article Sidebar
Published
May 6, 2022
Article Details
How to Cite
Brownstone, N., Zakria, D., Dirr, M., Lu, Y., & Rigel, D. (2022). Integrating Genomic Testing for Melanoma Into Your Practice. SKIN The Journal of Cutaneous Medicine, 6(3), 189–194. https://doi.org/10.25251/skin.6.3.2
Issue
Section
Clinical Management Recommendations
This work is licensed under a Creative Commons Attribution 4.0 International License.
All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.